The WHO’s chief scientific officer expressed hope for “second-generation” Covid-19 vaccines, including nasal spray and oral form.
Soumya Swaminathan, chief scientific officer of the World Health Organization (WHO), said on November 9 that there are 129 Covid-19 vaccines in human clinical trials and 194 others are being studied in the laboratory. .
“These vaccines are developed using all the technologies,” she said. “They’re still in development. I’m sure some will prove safe and effective, while others may not.”
“Some second-generation vaccines may have advantages, especially oral or nasal spray vaccines, because they are easier to put into the body than injectable vaccines. Finally, we can choose which ones to choose,” he said. Not only Covid-19, we can use these vaccine development platforms for other diseases in the future, “swaminathan said.
The WHO scientific team leader also explained the advantages of the nasal spray vaccine. “If there is a local immune response, the vaccine will tackle the virus before it gets into the lungs and starts to cause problems,” she said.
WHO has authorized the emergency use of seven Covid-19 vaccines, namely Pfizer/BioNTech, Moderna, AstraZeneca, Johnson & Johnson, Sinopharm, Sinovac and last week Bharat Biotech.
“No vaccine is 100% effective. No one dares to claim that a vaccine is 100% protective. But 90% is already a great number and offers protection, compared to zero,” Swaminathan emphasized. strong.
“Up to this point, the vaccines that we have approved have not shown any worrisome signals that we have to announce that they need to be reviewed,” she added.
The world has recorded 251,396,627 nCoV infections and 5,073,614 deaths, an increase of 420,467 and 6,730 respectively, while 225,854,556 people have recovered, according to real-time statistics site Worldometers. The whole world has used more than 7.25 billion doses of the Covid-19 vaccine.
Hong Hanh (Follow AFP)